Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(31 sites)
United States
Children's Hospital Los Angeles, Los Angeles, California Children's Hospital Orange County, Orange, California UCSF School of Medicine, San Francisco, California Children's Hospital Colorado, Denver, Colorado Children's National Medical Center, Washington D.C., District of Columbia Last updated December 2024